Do Participants Need to Be Reconsented When New Risks Are Discovered?

What Happens When You Learn Something New About the Risks?

A participant agreed to a study after being told about the risks known at the time. Months later, researchers learn about a previously unrecognized adverse effect, discover that a known complication occurs more often than expected, or receive other safety information that changes what is understood about participation.

The original consent may have been entirely appropriate when it was obtained. The problem is that the participant is now continuing under circumstances that were not fully known then.

Does that mean everyone must immediately sign a new consent form? Not necessarily. But significant new risk information cannot simply be ignored because participants already consented.

New Risks Must Be Assessed for Their Effect on Continued Participation

The Key Question Is Whether the New Risk Could Change the Participant's Decision

Consent Is Based on What Is Reasonably Known at the Time

Researchers cannot disclose risks that genuinely have not yet been identified. That does not make the original consent defective merely because knowledge later changes.

What matters is what happens after relevant new information becomes available. Informed consent is an ongoing process, so participants may need information that changes the basis on which they decide whether to remain in the research.

The U.S. Common Rule requires, when appropriate, that participants be informed of significant new findings developed during research that may relate to their willingness to continue. OHRP likewise explains that changes in risks may make it necessary to repeat or supplement the initial consent procedure.

Not Every Adverse Event Is Automatically a New Consent Risk

An adverse event occurring during a study and a newly established research risk are not necessarily the same thing. An event may ultimately be unrelated to the research intervention, already fall within the known risk profile, or provide too little evidence by itself to change what participants should be told.

The relevant safety and oversight processes must determine what the information means. Researchers should therefore avoid treating every reported event as proof of a new risk, but they should be equally careful not to dismiss emerging evidence simply because a particular risk was absent from the original consent document.

A Risk Can Be New Because Its Probability or Severity Has Changed

Researchers sometimes interpret “new risk” too narrowly. The harm itself does not have to be completely unknown. New evidence may show that a previously disclosed risk is substantially more frequent or more serious than participants were originally told.

SACHRP specifically identifies both newly discovered research-related risks and increases in the frequency or magnitude of previously described risks as examples of information that may affect willingness to continue and therefore should be disclosed. It also includes unanticipated problems that expose participants to new risks, such as a data breach.

Significance and Relevance Matter More Than the Mere Existence of New Information

Not every update to a safety profile carries the same ethical weight. A remote theoretical possibility supported by weak evidence may require a different response from a well-supported newly recognized serious harm.

SACHRP recommends considering the nature of the information and whether a reasonable person would regard it as important. The participant's status in the study also matters. Someone currently receiving an intervention associated with the new risk may need information that has little practical relevance to someone who completed that intervention years earlier.

This is one reason why the broader question of when participants should be asked to consent again cannot be reduced to a single automatic trigger.

Urgency Determines How Quickly Participants Need the Information

Some new information can wait for an orderly approved communication process. Other information cannot.

If a newly identified risk could affect an imminent procedure or expose participants to serious avoidable harm, delaying communication until the next routine visit may be inappropriate. SACHRP notes that the mechanism for providing new information should reflect factors including its urgency, complexity, the study, the population, and participants' stage in the research.

The safety reporting, protocol modification, and participant communication obligations applicable to the study should therefore be considered together rather than sequentially.

Disclosure Does Not Always Mean Full Reconsent

A particularly important distinction is between providing new risk information and conducting an entirely new consent process.

SACHRP notes that the Common Rule does not define “re-consent” as a regulatory term. Significant new information may be communicated through several mechanisms depending on the circumstances, including oral communication, an information sheet, an addendum, or a revised consent document. A complete renewed consent process may be appropriate for consequential changes, but it is not the only possible mechanism.

The method should therefore be proportionate to what participants need to understand and decide, while following the determination of the responsible ethics committee or institutional review board.

New Risk Information Can Change More Than the Risk Paragraph

Suppose evidence indicates not only a new adverse effect but also that the intervention is less effective than researchers initially expected. Participants may now be weighing greater risk against lower potential benefit.

SACHRP includes both increased or newly identified risks and decreases in expected benefit among information that may affect willingness to continue. It also identifies newly available alternative therapies as potentially relevant.

Researchers should therefore consider the participant's overall decision rather than mechanically editing a list of side effects.

New Risks Can Also Be Informational

Risk in research is not limited to physical injury. A breach involving identifiable research data, an unexpected possibility of re-identification, or another change in confidentiality protections may create new risks even though no clinical procedure has changed.

Whether such information requires notification, renewed consent, or another response depends on the facts and applicable law, regulation, ethics review, and institutional policy. SACHRP expressly identifies a data breach exposing participants to new risks as an example of information warranting consideration.

When a Previously Known Risk Becomes More Important

The example illustrates why “new risk” includes more than discovering an entirely new type of harm. A meaningful change in what researchers know about the likelihood or seriousness of an existing risk can also change the decision participants face.

Common Mistakes About Newly Discovered Risks

Assess the New Risk Through the Participant's Current Decision

When new safety information appears, begin by asking what it changes for participants rather than immediately asking whether a new form is needed.

In practical terms, ask whether the original consent still adequately represents the decision participants face now. If an important part of that decision has changed, the original signature should not be used as a reason to withhold the information.

When New Risk Information Emerges

Questions About New Risks and Reconsent

A New Risk Matters When It Changes the Decision Participants Face

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.